Clinical Pharmacokinetics of Lornoxicam

@article{Skjodt1998ClinicalPO,
  title={Clinical Pharmacokinetics of Lornoxicam},
  author={Neil M. Skjodt and Neal M. Davies},
  journal={Clinical Pharmacokinetics},
  year={1998},
  volume={34},
  pages={421-428}
}
SummaryLornoxicam (chlorotenoxicam) is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours). Lornoxicam is eliminated following biotransformation to 5′-hydroxy-lornoxicam, which does not undergo enterohepatic recirculation. Glucoroconjugated metabolites are excreted in urine and faeces with a half-life of about 11 hours.Lornoxicam and its metabolites bind extensively to plasma albumin… 
Bioequivalence of Lornocam Tablet to Xefo ® Tablet (Lornoxicam 4 mg)
TLDR
The criteria of the KFDA bioequivalence guideline were satisfied, indicating Lornocam tablet was bioequivalent to tablet, indicating there were no sequence effects between two formulations in these parameters.
Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype.
TLDR
The results show that the pharmacokinetics of lornoxicam are dependent on CYP2C9 polymorphism, and the presence of the CYP1C9*3 allele impairs the oral clearance of lORNoxicam.
Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.
  • C. Kohl, M. Steinkellner
  • Biology, Medicine
    Drug metabolism and disposition: the biological fate of chemicals
  • 2000
TLDR
The present results indicate that relatively close predictions of the interactions of lornoxicam with oral anticoagulants from in vitro data are possible under the assumption that hepatic lORNoxicam concentrations are similar to its total plasma concentrations.
Comparative Bioavailability of Lornoxicam as Single Doses of Quick-Release Tablet, Standard Tablet and Intramuscular Injection
TLDR
Lornoxicam-QR was comparable with lorn Toxicam-ST and lorn toxicam-IM regarding AUC∞, t1/2 and MRT, but both lornoxam-ZR and lORNoxicam -IM showed significantly shorter tmax and significantly higher Cmax values than lornoxicAM-ST.
IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?
TLDR
It was determined that CYP2C9 plays a relatively minor role in the overall clearance of sulindac, naproxen, ketoprofen, diclofenac, rofecoxib, and etoricoxib and CYP1C9 genotype would have no clinically meaningful impact on the pharmacokinetics of these drugs.
Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.
TLDR
The half-life, oral clearance and AUC(inf) of lornoxicam were similar in individuals with CYP2C9*1/*13 and those with CYp2C 9*1*3, although C(max) was higher in CYP1*1*/13 individuals, and a CYP3*1 /*3 genotype markedly reduced the conversion of lORNoxicam to 5'-hydroxylorn Toxicam.
Population pharmacokinetic analysis of lornoxicam in healthy Korean males considering creatinine clearance and CYP2C9 genetic polymorphism
TLDR
Individualized and effective lornoxicam therapy taking into account the genotype and degree of renal function of individuals will be possible in the future after a search for effective covariates that could explain the interindividual pharmacokinetic variability of lORNoxicam.
Cytochrome P450 Gene Polymorphisms and Variability in Response to NSAIDs
TLDR
The relative importance of further studies on the role of CYP2C genotypes with adverse reactions and other major issues to be investigated for NSAIDs known to be CYP 2C8 and/or CYP1C9 substrates is outlined.
Lornoxicam with Low-Dose Ketamine versus Pethidine to Control Pain of Acute Renal Colic
TLDR
Patients receiving lornoxicam-ketamine attained greater reduction in pain scores and less side effects with better functional state and also are less likely to require further analgesia than those administered pethidine to control acute renal colic pain.
Topical liquid crystalline gel containing lornoxicam/cyclodextrin complex
Lornoxicam is a potent analgesic non-steroidal anti-inflammatory drug that can be used topically to relieve pain and to reduce inflammation. The objectives of this study were to improve the
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Pharmacokinetics of lornoxicam in man.
TLDR
The results show that the parent compound and the main metabolite, 5'-hydroxy-lornoxicam, were found in plasma, however, in urine, no lORNoxicam was detected, only 5'-Hydroxy- lorn Toxicam.
Pharmacokinetics of Oxicam Nonsteroidal Anti-Inflammatory Agents
TLDR
Although the development of sudoxicam was stopped because of frequent adverse effects, this drug is interesting because, unlike other oxicams, its appears to have nonlinear elimination pharmacokinetics.
Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.
A series of studies in human subjects of potential interactions of lornoxicam with some other drugs is reviewed. No evidence of kinetic interaction was found with the antacids Maalox or Solugastrol,
Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam.
TLDR
In vitro and in vivo animal safety studies have demonstrated both subchronically and chronically that lornoxicam manifests no unusual toxicity, is not a mutagen nor is it tumorigenic and causes no fetal teratogenicity in reproduction studies.
Clinical Pharmacokinetics of Diclofenac
TLDR
Diclofenac is eliminated following biotransformation to glucoroconjugated and sulphate metabolites which are excreted in urine, very little drug is eliminated unchanged, and the excretion of conjugates may be related to renal function.
The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID.
TLDR
The results indicate that the concomitant administration of antacids did not influence the pharmacokinetic profile of LORNoxicam and confirm the short elimination half-life of Lornoxicam in man, which is markedly shorter than that of other oxicam-type compounds.
Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity.
TLDR
Six oxicams were compared in an attempt to understand why, despite close chemical structures, two of them were associated with an increased risk of toxicity in patients and different factors have been revealed.
Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions.
TLDR
Preliminary clinical trials suggest that lornoxicam is as effective as the opioid analgesics morphine, pethidine (meperidine) and tramadol in relieving postoperative pain following gynaecological or orthopaedic surgery, and aseffective as other NSAIDs after oral surgery.
Absorption of oral lornoxicam in healthy volunteers using a granular formulation in comparison with standard tablets.
TLDR
It was showed that lornoxicam granular formulation had a faster absorption than tablets even though the two formulations can be considered bioequivalent.
Does Bismuth Chelate Influence Lornoxicam Absorption?
TLDR
Lornoxicam is a novel NSAID at present undergoing clinical investigation,2 and a study has been carried out to investigate whether bismuth chelate influences absorption, and randomly allocated volunteers were randomly allocated to five treatments in two latin phases.
...
1
2
3
...